Intranasal Oxytocin Improves Behavior in Boys With Prader-Willi Syndrome
Three months of intranasal oxytocin improved social behavior and eating behavior in boys with Prader-Willi syndrome aged 3-11 years, with no safety concerns in this randomized crossover trial.
Quick Facts
What This Study Found
Intranasal oxytocin (16-40 IU/day for 3 months) improved social behavior and stabilized eating behavior in boys with PWS and in children with the deletion genotype, with no overall group effects.
Key Numbers
26 children; 16-40 IU/day; 3 months; boys: +4.5 vs -4.0 (P=.025); hyperphagia 0.0 vs -3.5 (P=.046); deletion subtype improved; no SAEs
How They Did This
Randomized, double-blind, placebo-controlled, crossover study in the Dutch PWS Reference Center. 26 children aged 3-11 years. Intranasal oxytocin 16-40 IU/day for 3 months. Outcomes: Oxytocin Questionnaire and Dykens hyperphagia questionnaire.
Why This Research Matters
PWS is characterized by severe behavioral challenges and uncontrollable hunger with no effective pharmacological treatment. Finding that oxytocin improves behavior in specific PWS subgroups opens a potential treatment avenue for this difficult condition.
The Bigger Picture
PWS results from dysfunction in the hypothalamic region where oxytocin is produced. Restoring oxytocin signaling through intranasal administration addresses a fundamental aspect of the syndrome's pathology, with potential to improve both social functioning and the devastating hyperphagia that defines the condition.
What This Study Doesn't Tell Us
Small sample size (n=26). Subgroup analyses (boys, deletion genotype) were not pre-specified primary outcomes. Crossover design assumes no carryover effects. Not all children showed benefit.
Questions This Raises
- ?Why does oxytocin benefit boys but not girls with PWS?
- ?What is the optimal long-term dosing of oxytocin for PWS?
- ?Should oxytocin treatment be initiated earlier in infancy for PWS?
Trust & Context
- Key Stat:
- Social behavior: +4.5 vs -4.0 (P=.025) Boys with PWS improved on oxytocin while deteriorating on placebo over 3 months
- Evidence Grade:
- Small randomized, double-blind, placebo-controlled crossover trial. Moderate evidence quality limited by sample size and post-hoc subgroup analyses.
- Study Age:
- Published in 2021, contributing to the growing evidence for oxytocin therapy in PWS and related neurodevelopmental conditions.
- Original Title:
- Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
- Published In:
- Clinical endocrinology, 94(5), 774-785 (2021)
- Authors:
- Damen, Layla, Grootjen, Lionne N, Juriaans, Alicia F, Donze, Stephany H, Huisman, T Martin, Visser, Jenny A, Delhanty, Patric J D, Hokken-Koelega, Anita C S
- Database ID:
- RPEP-05333
Evidence Hierarchy
Frequently Asked Questions
Can oxytocin help children with Prader-Willi syndrome?
This trial found that intranasal oxytocin improved social behavior and stabilized eating behavior in boys with PWS. Children with the deletion type of PWS also showed improvement. The treatment was safe and well-tolerated, but not all children benefited, so individual responses should be carefully monitored.
Why might oxytocin help with Prader-Willi syndrome?
PWS involves dysfunction in the hypothalamus, where oxytocin is produced. Patients with PWS may have impaired oxytocin signaling, contributing to social difficulties and eating problems. Intranasal oxytocin may partially restore this missing signaling.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05333APA
Damen, Layla; Grootjen, Lionne N; Juriaans, Alicia F; Donze, Stephany H; Huisman, T Martin; Visser, Jenny A; Delhanty, Patric J D; Hokken-Koelega, Anita C S. (2021). Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.. Clinical endocrinology, 94(5), 774-785. https://doi.org/10.1111/cen.14387
MLA
Damen, Layla, et al. "Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.." Clinical endocrinology, 2021. https://doi.org/10.1111/cen.14387
RethinkPeptides
RethinkPeptides Research Database. "Oxytocin in young children with Prader-Willi syndrome: Resul..." RPEP-05333. Retrieved from https://rethinkpeptides.com/research/damen-2021-oxytocin-in-young-children
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.